Antibody Drug Conjugate or ADCs are a class of biopharmaceutical medications planned as a focused on treatment for treating disease. In contrast to chemotherapy, ADCs are expected to target and murder tumor cells while saving solid cells. Starting at 2019, Antibody Drug Conjugate market to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents this market research report offering market values, size, share, growth, trend by 2023
The global antibody drug conjugate (ADC) market is projected to witness a stupendous growth at a notable 19% CAGR over the predicted years (2017-2023).
ADCs are made of three parts- first a specific antibody for binding, an antigen that has limited expression on the normal cells, second a cytotoxic agent to kill target cancer cells and third a chemical linker to attach the cytotoxic agent to the antibody. This is how antibody drug conjugates work. They are the new age of therapeutic agents. One of the key advantages of antibody drug conjugates is that this will help in bringing together the finest characteristics of both antibodies as well as the chemotherapy’s cytotoxic potential.
FREE Sample Pages at – https://www.marketresearchfuture.com/sample_request/1113
Leading players profiled in the antibody drug conjugate market include Synthon (U.S.), Mersana Therapeutics (U.S.), Oxford BioTherapeutics (U.S.), Heidelberg Pharma (Germany), Progenics Pharmaceuticals (U.S.), Astellas Pharma/Agensys (Japan), Bayer HealthCare (Germany), Agensys, Inc. (U.S.), Concortis Biotherapeutics (U.S.), Genentech (U.S.), AbbVie Inc. (U.S.), Millennium Pharmaceuticals (U.S.), Celldex Therapeutics (U.S.), Pfizer Inc. (U.S.), Immunomedics (U.S.), Antikor (U.K.), Roche Holding AG (Switzerland), ImmunoGen, Inc. (U.S.), and Seattle Genetics (U.S.).
As per MRFR report, the global antibody drug conjugate market is segmented on the basis of type, product, technology, application and end-user.
Based on type, it is segmented into drug/toxin, linker, monoclonal antibodies and others. Of these, the antibody drug conjugate linker is expected to have the maximum share in the antibody drug conjugate market.
Based on application, the antibody drug conjugate market is segmented into lymphoma, multiple myeloma, solid tumors, skin cancer, breast cancer, colon cancer, lung cancer, glioblastoma, ovary cancer, pancreas cancer, kidney cancer, prostate cancer and leukemia. Leukemia is further segmented into Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Acute Myeloid Leukemia (AML). Of these, breast cancer had the maximum share owing to its increasing prevalence.
Region-wise, the antibody drug conjugates market covers namely North America, Europe, Asia Pacific (APAC) and the Middle East and Africa (MEA).
North America has the largest market owing to the rising number of cancer patients in the region and increasing health awareness. The well-structured healthcare industry is also a significant factor that is promoting the medicine.
Europe is second in terms of volume of the market. The regional market experiences the same features as that of North America. In addition, the governments are also funding cancer-related industries heavily and have developed a robust infrastructure which helps in generating market share.
APAC has a huge market owing to the presence of developing countries such as India and China with a large population base that also has a significant number of patients with cancer. Furthermore, the region is open to adopting the latest technologies and integrates western treatment options in its regulatory framework to improve the quality of public life.
- The market is still developing and each day brings in new information regarding advancements. Efforts of Creative Biolabs in introducing a maytansinoid-payload for ADCs better performance can be considered exemplary. In Antibody Drug Conjugate Market, the link between the antibody and the cytotoxic agent is crucial. Broadpharm has introduced a polyethylene glycol (PEG) product, a linker that has features such as high water solubility, reduced aggregation, and low immunogenicity. In addition, Glykos Finland and OcellO of The Netherlands have developed a hydrophilic auristatin payload that betters ADCs efficacy and biocompatibility.
- Feb 2019- The Food and Drug Administration (FDA) has granted priority review to ADC (antibody drug conjugate) for diffusing large B-Cell Lymphoma. The chief medical officer of global product
- August 19, 2019 – Development is working with the Food and Drug Administration for bringing this vital novel option to patients having this aggressive ailment as fast as possible. The FDA is most likely to come up with the decision.
- Jan 2019- Daiichi Sankyo has come up with a late-stage study of Antibody Drug Conjugate Market to treat patients having low expressing HER2 metastatic/ unrespectable breast cancer.
Get Complete Report Details with Detail Tables and Figures @ https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312